Stock Detail
EMERGENT BIOSOLUTIONS INC
Sector: Biotechnology
Latest Quote @ Wed May 5 20:33:37 (15 min delayed)
| $12.93 |
$18.04 |
$14.25 |
+0.04 |
0.28% |
|
Last Day's Data
| $14.21 |
$14.39 |
$0.00 |
0.00% |
0.00 |
$14.34 |
| $14.35 |
$14.13 |
85,101.00 |
513.28M |
249,132.00 |
23.14 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 14.50 |
14.35 |
14.24 |
14.09 |
13.98 |
Stock Profile
Emergent BioSolutions, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of immunobiotics primarily in the United States. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body's immune system to prevent diseases. The company operates in two segments, Biodefense and Commercial. The Biodefense segment develops, manufactures, and commercializes immunobiotics for use against biological agents. This segment's primary product is BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax immune globulin, for post-exposure treatment of anthrax infection; Botulinum immune globulin for post-exposure treatment of illness caused by botulinum toxin; and Recombinant bivalent botulinum vaccine, a prophylaxis for illness caused by botulinum toxin. The Commercial segment develops immunobiotics for use against infectious diseases. This segment's product portfolio includes Typhoid vaccine, a single-dose vaccine in phase II clinical development; Hepatitis B therapeutic vaccine, for treating chronic carriers of hepatitis B infection, which is in phase II clinical development; and Group B streptococcus vaccine, a product in phase I clinical trial for administration to women of childbearing age for protection of the fetus and newborn babies. In addition, Emergent BioSolutions is developing a chlamydia vaccine and a meningitis B vaccine, which are in preclinical development. The company serves primarily the U.S. Department of Defense and the U.S. Department of Health and Human Services. It has collaboration agreements with U.K. Health Protection Agency for the development of a human botulinum immune globulin candidate; and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland.
